JPH07504204A - 免疫増強剤およびその生理的に容認可能な塩 - Google Patents

免疫増強剤およびその生理的に容認可能な塩

Info

Publication number
JPH07504204A
JPH07504204A JP6508846A JP50884693A JPH07504204A JP H07504204 A JPH07504204 A JP H07504204A JP 6508846 A JP6508846 A JP 6508846A JP 50884693 A JP50884693 A JP 50884693A JP H07504204 A JPH07504204 A JP H07504204A
Authority
JP
Japan
Prior art keywords
physiologically acceptable
hydrogen
formula
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP6508846A
Other languages
English (en)
Japanese (ja)
Inventor
ローデス，ジョン　リチャード
Original Assignee
ザ　ウエルカム　ファウンデーション　リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220715A external-priority patent/GB9220715D0/en
Priority claimed from GB929226874A external-priority patent/GB9226874D0/en
Application filed by ザ　ウエルカム　ファウンデーション　リミテッド filed Critical ザ　ウエルカム　ファウンデーション　リミテッド
Publication of JPH07504204A publication Critical patent/JPH07504204A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Securing Globes, Refractors, Reflectors Or The Like (AREA)
  • Planar Illumination Modules (AREA)
  • Illuminated Signs And Luminous Advertising (AREA)
JP6508846A 1992-10-01 1993-09-30 免疫増強剤およびその生理的に容認可能な塩 Withdrawn JPH07504204A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9220715.8 1992-10-01
GB929220715A GB9220715D0 (en) 1992-10-01 1992-10-01 Immunopotentiatory agent and physiologically acceptable salts thereof
GB929226874A GB9226874D0 (en) 1992-12-23 1992-12-23 Immunopotentiatory agents and physiologically acceptable salts thereof
GB9226874.7 1992-12-23
PCT/GB1993/002039 WO1994007479A2 (en) 1992-10-01 1993-09-30 Immunopotentiatory agents

Publications (1)

Publication Number Publication Date
JPH07504204A true JPH07504204A (ja) 1995-05-11

Family

ID=26301715

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6508846A Withdrawn JPH07504204A (ja) 1992-10-01 1993-09-30 免疫増強剤およびその生理的に容認可能な塩
JP27730093A Expired - Fee Related JP3717950B2 (ja) 1992-10-01 1993-09-30 免疫強化剤及び生理学的に許容され得るその塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP27730093A Expired - Fee Related JP3717950B2 (ja) 1992-10-01 1993-09-30 免疫強化剤及び生理学的に許容され得るその塩

Country Status (24)

Country Link
US (1) US5508310A (OSRAM)
EP (3) EP0678298A3 (OSRAM)
JP (2) JPH07504204A (OSRAM)
KR (1) KR100348775B1 (OSRAM)
CN (1) CN1213746C (OSRAM)
AT (1) ATE146075T1 (OSRAM)
AU (1) AU676491B2 (OSRAM)
CA (1) CA2124677C (OSRAM)
CZ (1) CZ132794A3 (OSRAM)
DE (1) DE69306545T2 (OSRAM)
DK (1) DK0609606T3 (OSRAM)
ES (1) ES2096215T3 (OSRAM)
GR (1) GR3022541T3 (OSRAM)
HR (1) HRP931243A2 (OSRAM)
HU (1) HUT70482A (OSRAM)
IL (1) IL107157A0 (OSRAM)
MX (1) MX9306079A (OSRAM)
NZ (1) NZ256110A (OSRAM)
RU (1) RU94028670A (OSRAM)
SG (1) SG48993A1 (OSRAM)
SI (1) SI9300514A (OSRAM)
SK (1) SK65294A3 (OSRAM)
WO (1) WO1994007479A2 (OSRAM)
YU (1) YU62793A (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534681A (ja) * 2004-04-24 2007-11-29 キム、サン‐ヒ モノアセチルジアシルグリセロール誘導体を有効成分として含有する免疫調節剤、抗癌剤及び健康食品

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
WO1998052573A1 (en) * 1997-05-20 1998-11-26 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
KR100680014B1 (ko) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
WO2001046125A2 (en) * 1999-12-21 2001-06-28 Astrazeneca Ab Cd45 inhibitors
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
EP1265840A2 (en) * 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
NZ521898A (en) 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
AU2001251491A1 (en) * 2000-04-11 2001-10-23 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
PL367102A1 (en) * 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
ES2338305T3 (es) * 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
AU2004241107A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
SG10202009963PA (en) 2011-01-07 2020-11-27 Allergan Inc Melanin modification compositions and methods of use
SG10202008673WA (en) 2015-03-06 2020-10-29 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
JP2019511565A (ja) * 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
JPS5545658A (en) * 1978-09-28 1980-03-31 Rikagaku Kenkyusho Carcinostatic agent
JPS5569510A (en) * 1978-11-16 1980-05-26 Mitsubishi Chem Ind Ltd Carcinostatic agent
GR76950B (OSRAM) * 1980-12-18 1984-09-04 Wellcome Found
LU85365A1 (de) * 1984-05-16 1986-01-29 Chimicasa Gmbh Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) * 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) * 1985-08-09 1987-02-19 Schleicher Peter Mundpflegemittel
JPS63264409A (ja) * 1988-01-13 1988-11-01 Rikagaku Kenkyusho 制癌剤
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
EP0499015A1 (en) * 1991-02-15 1992-08-19 Fockerman, Jasmine Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534681A (ja) * 2004-04-24 2007-11-29 キム、サン‐ヒ モノアセチルジアシルグリセロール誘導体を有効成分として含有する免疫調節剤、抗癌剤及び健康食品

Also Published As

Publication number Publication date
RU94028670A (ru) 1996-05-20
CA2124677A1 (en) 1994-04-14
NZ256110A (en) 1997-07-27
CA2124677C (en) 2008-09-09
EP0678298A3 (en) 1996-05-29
WO1994007479A2 (en) 1994-04-14
ES2096215T3 (es) 1997-03-01
US5508310A (en) 1996-04-16
KR100348775B1 (ko) 2003-02-11
HRP931243A2 (en) 1995-12-31
GR3022541T3 (en) 1997-05-31
AU676491B2 (en) 1997-03-13
MX9306079A (es) 1994-06-30
HU9401631D0 (en) 1994-08-29
CZ132794A3 (en) 1995-02-15
ATE146075T1 (de) 1996-12-15
EP0609606B1 (en) 1996-12-11
YU62793A (sh) 1998-05-15
EP0614357A1 (en) 1994-09-14
JPH072660A (ja) 1995-01-06
CN1213746C (zh) 2005-08-10
HUT70482A (en) 1995-10-30
EP0609606A1 (en) 1994-08-10
JP3717950B2 (ja) 2005-11-16
AU4831193A (en) 1994-04-26
CN1091005A (zh) 1994-08-24
DE69306545T2 (de) 1997-04-03
IL107157A0 (en) 1993-12-28
SG48993A1 (en) 1998-05-18
WO1994007479A3 (en) 1994-07-21
DE69306545D1 (de) 1997-01-23
DK0609606T3 (OSRAM) 1997-03-17
SK65294A3 (en) 1995-03-08
SI9300514A (en) 1994-06-30
EP0678298A2 (en) 1995-10-25

Similar Documents

Publication Publication Date Title
AU676491B2 (en) Immunopotentiatory agents
JP5769762B2 (ja) 治療組成物およびその使用
AU767892B2 (en) New combined preparation for the treatment of neoplasic diseases or of infectious diseases
JP2016536286A (ja) ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
JP2002523378A (ja) Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
US20060079510A1 (en) Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
KR101909433B1 (ko) 키나제 저해제의 부작용 저감제
JP2005512998A (ja) 抗マラリア治療剤に対する新規の使用
JP2020059703A (ja) 免疫除去療法
JP4627356B2 (ja) ウイルス性心筋炎の予防または治療薬剤
JP2025536179A (ja) 免疫チェックポイント遮断に基づく抗腫瘍医薬組成物及びその応用
US20040120926A1 (en) Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment
US5872151A (en) Immunopotentiatory agents and physiologically acceptable salts thereof
US5958980A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
JP2004538319A (ja) 抗−ｈｉｖ治療のためのｒ−ｎｓａｉｄ化合物の用途
AU2019392742B2 (en) Anti-cancer activity of adamantane derivatives
US5616578A (en) Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
KR0178762B1 (ko) 특정 인돌 유도체의 신규 의약적 용도 및 그를 함유하는 제약 조성물
US6096786A (en) Immunopotentiatory agent and physiologically acceptable salts thereof
CN110151775A (zh) Hsp90抑制剂17-DMAG在制备抑制儿童急性淋巴细胞白血病药物中的应用
US20230078120A1 (en) Methods for Treating Coronavirus Infections
JPH02117621A (ja) 抗ウイルス医薬組成物
JPH0222227A (ja) エイズカヘキシーの酢酸メゲストロールによる処置法
JPH06199674A (ja) 日和見感染症の治療・予防に関する医薬
CA1332222C (en) Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081008

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091008

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091008

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101008

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111008

Year of fee payment: 12

LAPS Cancellation because of no payment of annual fees